NDAINJECTIONINJECTABLE
Approved
Feb 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
UVADEX (methoxsalen) by Teva is photoabsorption [moa]. Approved for graft versus host disease. First approved in 1999.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UVADEX (methoxsalen) is a photoactivated radical generator administered by injection for the treatment of graft-versus-host disease (GVHD). The drug works through photoabsorption, generating reactive oxygen species when exposed to light to suppress T-cell mediated immune responses. It represents a niche immunosuppressive therapy for a serious post-transplant complication.
LOE Approaching
Product is nearing loss of exclusivity with minimal current commercial visibility; career opportunities likely limited to specialized hematology/oncology or specialty pharmacy teams at Teva.
Mechanism of Action
Photoabsorption
Pharmacologic Class:
Photoactivated Radical Generator
Indications (1)
Clinical Trials (2)
Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease
Started May 2020
24 enrolled
Acute-graft-versus-host Disease
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
Started Nov 2011
60 enrolled
Chronic Graft Versus Host Disease
Worked on UVADEX at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.